Devises / ALLO
ALLO: Allogene Therapeutics Inc
1.13
USD
0.05
(4.24%)
Le taux de change de ALLO a changé de -4.24% aujourd'hui. Au cours de la journée, l'instrument a été échangé à un minimum de 1.11 et à un maximum de 1.20.
Suivez la dynamique Allogene Therapeutics Inc. Les cotations en temps réel vous aideront à réagir rapidement aux changements du marché. En basculant entre différentes périodes, vous pouvez surveiller les tendances et la dynamique des taux de change par minutes, heures, jours, semaines et mois. Utilisez ces informations pour prévoir les changements du marché et prendre des décisions de trading éclairées.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
ALLO Nouvelles
- Fate Therapeutics: Recent Update Met With Selling, But Positives Exist
- Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO)
- Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
- Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript
- Allogene Q2 Cash Tops $300 Million
- Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts
- Allogene stock continues ALPHA3 trial with standard FC regimen after safety event
- Allogene stock maintains Market Perform rating at Citizens JMP after trial adjustment
- This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Allogene Therapeutics (NASDAQ:ALLO), AvalonBay Communities (NYSE:AVB)
- Allogene Resets Clinical Course After Patient Death In Lymphoma Study - Allogene Therapeutics (NASDAQ:ALLO)
- Adicet Bio stock rating initiated at Buy by H.C. Wainwright
- Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
- Allogene Therapeutics at Jefferies Conference: Delays and Optimism
- Citi maintains buy rating on Allogene stock following ASCO data
- H.C. Wainwright maintains buy rating on Allogene stock after ASCO update
- Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
- Citizens JMP highlights key ASCO presentations
- Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment
- Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner
- Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
- Allogene shares update on CAR T-cell therapies at ASCO meeting
- Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays
- Abrdn Life Sciences Investors Q4 2024 Commentary (NYSE:HQL)
Range quotidien
1.11
1.20
Range Annuel
0.86
3.78
- Clôture Précédente
- 1.18
- Ouverture
- 1.18
- Bid
- 1.13
- Ask
- 1.43
- Plus Bas
- 1.11
- Plus Haut
- 1.20
- Volume
- 1.878 K
- Changement quotidien
- -4.24%
- Changement Mensuel
- -5.83%
- Changement à 6 Mois
- -39.25%
- Changement Annuel
- -56.37%
30 août, samedi